255 related articles for article (PubMed ID: 36700223)
1. Pre-clinical models for evaluating glioma targeted immunotherapies.
Frederico SC; Zhang X; Hu B; Kohanbash G
Front Immunol; 2022; 13():1092399. PubMed ID: 36700223
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for glioma: Current management and future application.
Xu S; Tang L; Li X; Fan F; Liu Z
Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356
[TBL] [Abstract][Full Text] [Related]
3. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
4. Single vs. combination immunotherapeutic strategies for glioma.
Chandran M; Candolfi M; Shah D; Mineharu Y; Yadav VN; Koschmann C; Asad AS; Lowenstein PR; Castro MG
Expert Opin Biol Ther; 2017 May; 17(5):543-554. PubMed ID: 28286975
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
Garcia-Fabiani MB; Ventosa M; Comba A; Candolfi M; Nicola Candia AJ; Alghamri MS; Kadiyala P; Carney S; Faisal SM; Schwendeman A; Moon JJ; Scheetz L; Lahann J; Mauser A; Lowenstein PR; Castro MG
Expert Opin Investig Drugs; 2020 Jul; 29(7):659-684. PubMed ID: 32400216
[TBL] [Abstract][Full Text] [Related]
6. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell immunotherapy for malignant gliomas.
Luptrawan A; Liu G; Yu JS
Rev Recent Clin Trials; 2008 Jan; 3(1):10-21. PubMed ID: 18474011
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
9. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.
Franson A; McClellan BL; Varela ML; Comba A; Syed MF; Banerjee K; Zhu Z; Gonzalez N; Candolfi M; Lowenstein P; Castro MG
Front Med (Lausanne); 2022; 9():966458. PubMed ID: 36186781
[TBL] [Abstract][Full Text] [Related]
10. Therapy for recurrent malignant glioma in adults.
Mrugala MM; Kesari S; Ramakrishna N; Wen PY
Expert Rev Anticancer Ther; 2004 Oct; 4(5):759-82. PubMed ID: 15485312
[TBL] [Abstract][Full Text] [Related]
11. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
[TBL] [Abstract][Full Text] [Related]
12. Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.
Garcia-Fabiani MB; Haase S; Comba A; Carney S; McClellan B; Banerjee K; Alghamri MS; Syed F; Kadiyala P; Nunez FJ; Candolfi M; Asad A; Gonzalez N; Aikins ME; Schwendeman A; Moon JJ; Lowenstein PR; Castro MG
Front Oncol; 2021; 11():631037. PubMed ID: 34168976
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
14. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
15. Immunometabolism, a new therapeutic development for immunotherapies of high-grade gliomas: a narrative review.
Wu JY; Ren AL; Lim M
Chin Clin Oncol; 2022 Aug; 11(4):26. PubMed ID: 36098097
[TBL] [Abstract][Full Text] [Related]
16. Considerations when treating high-grade pediatric glioma patients with immunotherapy.
Crotty E; Downey K; Ferrerosa L; Flores C; Hegde B; Raskin S; Hwang E; Vitanza N; Okada H
Expert Rev Neurother; 2021 Feb; 21(2):205-219. PubMed ID: 33225764
[TBL] [Abstract][Full Text] [Related]
17. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
Agarwal P; Aiyer HM
Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
[TBL] [Abstract][Full Text] [Related]
18. Radiation and Immunotherapy in High-grade Gliomas: Where Do We Stand?
Reznik E; Smith AW; Taube S; Mann J; Yondorf MZ; Parashar B; Wernicke AG
Am J Clin Oncol; 2018 Feb; 41(2):197-212. PubMed ID: 28906259
[TBL] [Abstract][Full Text] [Related]
19. The role of emerging therapy in the management of patients with diffuse low grade glioma.
Sloan AE; Okada H; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):631-5. PubMed ID: 26530260
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Ferguson SD; Srinivasan VM; Ghali MG; Heimberger AB
Immunotherapy; 2016; 8(4):413-23. PubMed ID: 26973123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
